X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4467) 4467
Publication (648) 648
Book Review (68) 68
Book Chapter (18) 18
Dissertation (8) 8
Conference Proceeding (3) 3
Magazine Article (2) 2
Newspaper Article (2) 2
Book / eBook (1) 1
Data Set (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3010) 3010
immunotherapy (2295) 2295
pd-1 (1938) 1938
humans (1906) 1906
oncology (1758) 1758
cancer (1690) 1690
immunology (1426) 1426
lymphocytes (1226) 1226
pd-1 protein (1111) 1111
tumors (1108) 1108
t cells (990) 990
animals (973) 973
lymphocytes t (963) 963
melanoma (959) 959
pd-1 blockade (930) 930
apoptosis (903) 903
expression (864) 864
female (807) 807
immune checkpoint (793) 793
pd-l1 (769) 769
nivolumab (719) 719
care and treatment (670) 670
pd-l1 protein (644) 644
male (635) 635
antigens (628) 628
ligands (619) 619
mice (619) 619
blockade (598) 598
patients (594) 594
chemotherapy (565) 565
t-cells (556) 556
research (552) 552
metastasis (549) 549
immune system (515) 515
cancer therapies (508) 508
ipilimumab (485) 485
middle aged (484) 484
immune response (483) 483
pembrolizumab (482) 482
article (478) 478
health aspects (473) 473
cell death (456) 456
cytotoxicity (455) 455
analysis (445) 445
cell biology (440) 440
lung cancer (429) 429
dendritic cells (417) 417
ctla-4 (410) 410
gene expression (410) 410
therapy (407) 407
clinical trials (403) 403
activation (398) 398
safety (398) 398
cd8 antigen (396) 396
programmed cell death 1 receptor - antagonists & inhibitors (393) 393
adult (388) 388
cytokines (381) 381
aged (375) 375
programmed cell death 1 receptor - metabolism (372) 372
immunity (371) 371
survival (367) 367
t cell receptors (367) 367
review (360) 360
biomarkers (352) 352
immunotherapy - methods (352) 352
programmed cell death 1 receptor - immunology (352) 352
metastases (350) 350
medical research (348) 348
open-label (346) 346
medicine, research & experimental (345) 345
mutation (338) 338
medicine & public health (337) 337
multidisciplinary sciences (337) 337
prognosis (333) 333
antibodies (331) 331
proteins (328) 328
medical prognosis (323) 323
t-lymphocytes - immunology (318) 318
tumor-infiltrating lymphocytes (315) 315
cd8-positive t-lymphocytes - immunology (310) 310
flow cytometry (310) 310
medicine (310) 310
metastatic melanoma (306) 306
responses (303) 303
genetic aspects (297) 297
neoplasms - immunology (297) 297
b7-h1 antigen - metabolism (295) 295
tumor microenvironment (292) 292
regulatory t-cells (290) 290
exhaustion (280) 280
hematology (280) 280
antibodies, monoclonal - therapeutic use (273) 273
drug therapy (273) 273
research article (270) 270
development and progression (269) 269
neoplasms. tumors. oncology. including cancer and carcinogens (266) 266
cell lung-cancer (264) 264
immunohistochemistry (263) 263
usage (262) 262
immunoglobulins (261) 261
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4451) 4451
French (9) 9
German (7) 7
Chinese (3) 3
Japanese (3) 3
Hungarian (1) 1
Korean (1) 1
Polish (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 09/2016, Volume 22, Issue 18, pp. 4585 - 4593
Journal Article
Journal Article
FRONTIERS IN ONCOLOGY, ISSN 2234-943X, 01/2015, Volume 4, p. 385
Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy.These... 
RESPONSES | MELANOMA | nivolumab | ONCOLOGY | SAFETY | CLTA-4 | ipilimumab | immunotherapy | ANTIBODY | ANTI-PD-1 | PD-1 | T-CELLS | Immunotherapy | Nivolumab
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2019, Volume 120, Issue 1, pp. 3 - 5
Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of... 
MULTICENTER | PEMBROLIZUMAB | ONCOLOGY | SAFETY | OPEN-LABEL | NIVOLUMAB | DOCETAXEL | Medical research | Sensitivity | PD-1 protein | Immunotherapy | PD-L1 protein | Clinical trials | Subgroups | Cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2017, Volume 23, Issue 20, pp. 6178 - 6189
Purpose: Carcinoembryonic antigen (CEA) is a candidate target for cellular immunotherapy of pancreatic cancer. In this study, we have characterized the... 
SURVIVAL | RESPONSES | OVEREXPRESSION | DENDRITIC CELLS | ONCOLOGY | IMMUNOTHERAPY | ADENOCARCINOMA | IMMUNOGLOBULIN | ANTIBODY | CARCINOMA | EXPRESSION | T-Lymphocyte Subsets - immunology | Pancreatic Neoplasms - metabolism | Humans | Middle Aged | Hepatitis A Virus Cellular Receptor 2 - metabolism | Male | Biomarkers, Tumor | T-Lymphocytes, Cytotoxic - drug effects | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | T-Lymphocyte Subsets - drug effects | T-Cell Antigen Receptor Specificity - immunology | Aged, 80 and over | Adult | Female | Pancreatic Neoplasms - mortality | Cytotoxicity, Immunologic - drug effects | T-Lymphocytes, Cytotoxic - immunology | Cytokines - metabolism | Signal Transduction | Carcinoembryonic Antigen - immunology | Pancreatic Neoplasms - pathology | Programmed Cell Death 1 Receptor - metabolism | Immunophenotyping | Antineoplastic Agents, Immunological - pharmacology | B7-H1 Antigen - metabolism | T-Lymphocytes, Cytotoxic - metabolism | T-Lymphocyte Subsets - metabolism | Pancreatic Neoplasms - immunology | Cell Line, Tumor | Aged | Cytotoxicity, Immunologic - immunology | Neoplasm Staging | Flow cytometry | Biotechnology | Peptides | PD-1 protein | Toxicity | CD8 antigen | Cytotoxicity | Leukocytes (mononuclear) | Lymphocytes T | Lymph nodes | Carcinoembryonic antigen | Lymphocytes | Immunotherapy | Peripheral blood mononuclear cells | Antigens | Cytokines | Secretion | T cell receptors | Tumor cell lines | Patients | Drainage | Cytometry | Experimental design | Pancreatic cancer | γ-Interferon | PD-L1 protein | Fluorescein | Cell lines | Histocompatibility antigen HLA | Cancer | PD-L1 | cytotoxic T lymphocytes | TIM-3 | PD-1
Journal Article
Birth Defects Research Part B: Developmental and Reproductive Toxicology, ISSN 1542-9733, 04/2016, Volume 107, Issue 2, pp. 108 - 119
Journal Article
Cancer Biology and Medicine, ISSN 2095-3941, 05/2018, Volume 15, Issue 2, pp. 116 - 123
Cancer immunotherapy has greatly advanced in recent years, and PD-1/PD-L1 blocking therapy has become a major pillar of immunotherapy. Successful clinical... 
PD-L1 | Cancer immunotherapy | PD-1 | MEDICINE, RESEARCH & EXPERIMENTAL | MULTICENTER | OPEN-LABEL | SINGLE-ARM | CHECKPOINT BLOCKADE | LUNG-CANCER | ONCOLOGY | ADVANCED MELANOMA | cancer immunotherapy | SQUAMOUS-CELL CARCINOMA | NIVOLUMAB | CLINICAL-SIGNIFICANCE | Review
Journal Article
American journal of respiratory and critical care medicine, ISSN 1073-449X, 2014, Volume 190, Issue 5, pp. 560 - 571
Journal Article
Translational Cancer Research, ISSN 2218-676X, 06/2018, Volume 7, Issue 3, pp. 462 - 471
Background: Recent clinical studies have shown promise for targeting programmed cell death protein-1 (PD-1) and programmed cell death ligand 1 (PD-L1)... 
Programmed cell death protein1 (PD-1) | Janus kinase 2 (JAK2) | The Cancer Genome Atlas (TCGA) | Immunotherapy | IFN-GAMMA | programmed cell death protein1 (PD-1) | TUMORS | NECK-CANCER | CHECKPOINT BLOCKADE | PATHWAY BLOCKADE | LUNG-CANCER | CYTOLYTIC ACTIVITY | T-CELL INFILTRATION | ONCOLOGY | RESISTANCE | EXPRESSION
Journal Article
Retrovirology, ISSN 1742-4690, 02/2015, Volume 12, Issue 1, pp. 14 - 14
Journal Article